Omeros Co. (NASDAQ:OMER) Given Consensus Rating of "Moderate Buy" by Brokerages

Omeros Co. (NASDAQ:OMER - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $22.50.

A number of research analysts recently commented on OMER shares. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, April 1st. StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Truvestments Capital LLC boosted its holdings in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,669 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Omeros in the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets grew its holdings in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its stake in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 4,404 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Stock Performance

Shares of NASDAQ OMER traded down $0.30 during trading on Wednesday, hitting $7.06. 802,194 shares of the company were exchanged, compared to its average volume of 552,480. The company has a fifty day moving average price of $8.56 and a 200-day moving average price of $7.68. The firm has a market capitalization of $409.93 million, a PE ratio of -3.06 and a beta of 2.35. Omeros has a 12-month low of $2.97 and a 12-month high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same quarter in the previous year, the company earned ($0.15) EPS. Research analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.